Treatment strategies for gastric cancer patients with peritoneal metastasis.

Abstract

Although the treatment of gastric cancer improves the clinical outcomes, the survival of gastric cancer patients with peritoneal metastasis is still very poor. Effective drugs against peritoneal metastasis, coupled with new therapeutic modalities, are needed to improve the prognoses of these patients. Paclitaxel and TS-1 are candidate drugs for peritoneal metastasis, and intraperitoneal chemotherapy and targeted therapy are potential new therapeutic modalities. Two phase II studies using TS-1 and intraperitoneal and systemic paclitaxel for gastric cancer patients with peritoneal metastasis showed respectable survival results. In addition, peritoneal metastatic lesions showed high levels of epithelial cellular adhesion molecule (ECAM) and very low levels of human epidermal growth factor receptor 2 (HER2), thus indicating that an anti-ECAM monoclonal antibody, catumaxomab, would be effective against gastric cancer-derived peritoneal metastasis. Although catumaxomab and intraperitoneally administered paclitaxel are not generally used in Japan at present, these treatment strategies might therefore be effectively used in Japan in the near future.

• Authors: Motohiro Imano, Kiyotaka Okuno
• Journal: Surgery today (Surg Today) Vol. 44 Issue 3 Pg. 399-404 (Mar 2014) ISSN: 1436-2813 [Electronic] Japan
• PMID: 23677598 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Bispecific
• Antibodies, Monoclonal
• Antigens, Neoplasm
• Cell Adhesion Molecules
• Epithelial Cell Adhesion Molecule
• Silicates
• titanium silicide
• Titanium
• ERBB2 protein, human
• Receptor, ErbB-2
• catumaxomab
• Paclitaxel

Topics

• Antibodies, Bispecific (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antigens, Neoplasm (immunology, metabolism)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cell Adhesion Molecules (immunology, metabolism)
• Clinical Trials, Phase II as Topic
• Epithelial Cell Adhesion Molecule
• Humans
• Infusions, Parenteral
• Molecular Targeted Therapy
• Paclitaxel (administration & dosage)
• Peritoneal Neoplasms (genetics, secondary, therapy)
• Prognosis
• Receptor, ErbB-2 (metabolism)
• Silicates (administration & dosage)
• Stomach Neoplasms (pathology, therapy)
• Survival Rate
• Titanium (administration & dosage)